• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

腹股沟淋巴结转移中具有软骨肉瘤分化的突变型恶性黑色素瘤。

-mutated malignant melanoma with chondrosarcomatous differentiation in inguinal nodal metastasis.

作者信息

Abbati Francesca, Altimari Annalisa, Corti Barbara, Dika Emi, Sperandi Francesca, Melotti Barbara

机构信息

Department of Medical Oncology IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy.

Laboratory of Oncologic Molecular Pathology IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy.

出版信息

Clin Case Rep. 2021 Mar 7;9(4):2200-2204. doi: 10.1002/ccr3.3982. eCollection 2021 Apr.

DOI:10.1002/ccr3.3982
PMID:33936664
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8077358/
Abstract

We report the case of a young woman who developed metastatic melanoma in the inguinal nodal region, which acquired chondrosarcomatous differentiation and preserved the BRAF mutation found in the primary tumor. The patient was treated with a BRAF/MEK inhibitor combination therapy (dabrafenib/trametinib), which was demonstrated to be effective and well-tolerated.

摘要

我们报告了一名年轻女性的病例，该患者在腹股沟淋巴结区域发生了转移性黑色素瘤，该肿瘤获得了软骨肉瘤样分化，并保留了原发肿瘤中发现的BRAF突变。患者接受了BRAF/MEK抑制剂联合治疗（达拉非尼/曲美替尼），结果显示该治疗有效且耐受性良好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e69a/8077358/5c012e368ab8/CCR3-9-2200-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e69a/8077358/ed9cb90fbd4d/CCR3-9-2200-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e69a/8077358/432480c93092/CCR3-9-2200-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e69a/8077358/5c012e368ab8/CCR3-9-2200-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e69a/8077358/ed9cb90fbd4d/CCR3-9-2200-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e69a/8077358/432480c93092/CCR3-9-2200-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e69a/8077358/5c012e368ab8/CCR3-9-2200-g002.jpg

相似文献

1
-mutated malignant melanoma with chondrosarcomatous differentiation in inguinal nodal metastasis.腹股沟淋巴结转移中具有软骨肉瘤分化的突变型恶性黑色素瘤。
Clin Case Rep. 2021 Mar 7;9(4):2200-2204. doi: 10.1002/ccr3.3982. eCollection 2021 Apr.
2
Early Experience with Dabrafenib-Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma-A Single-Center Experience.达拉非尼-曲美替尼联合治疗BRAF突变型恶性黑色素瘤患者的早期经验——单中心经验
South Asian J Cancer. 2021 Nov 24;10(3):187-189. doi: 10.1055/s-0041-1736032. eCollection 2021 Sep.
3
Trametinib: a MEK inhibitor for management of metastatic melanoma.曲美替尼：一种用于治疗转移性黑色素瘤的MEK抑制剂。
Onco Targets Ther. 2015 Aug 25;8:2251-9. doi: 10.2147/OTT.S72951. eCollection 2015.
4
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.达拉非尼联合曲美替尼治疗 BRAF 和 MEK 抑制剂预处理的晚期 BRAF 突变型黑色素瘤患者：一项开放标签、单臂、双中心、Ⅱ期临床研究。
Lancet Oncol. 2017 Apr;18(4):464-472. doi: 10.1016/S1470-2045(17)30171-7. Epub 2017 Mar 4.
5
Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.真心话大冒险：在转移性黑色素瘤患者发生急性间质性肾炎后切换 BRAF/MEK 抑制剂——病例报告及文献复习。
Acta Clin Belg. 2023 Jun;78(3):215-222. doi: 10.1080/17843286.2022.2114684. Epub 2022 Aug 23.
6
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.辅助达拉非尼联合曲美替尼治疗 BRAF 突变型 III 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
7
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).达拉非尼联合曲美替尼治疗 BRAF V600 突变型转移性黑色素瘤患者有效：来自达拉非尼联合曲美替尼命名患者项目（DESCRIBE II）的患者分析。
Melanoma Res. 2020 Jun;30(3):261-267. doi: 10.1097/CMR.0000000000000654.
8
Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.达拉非尼联合曲美替尼：治疗 BRAF(V600) 突变型晚期黑色素瘤的药物评价。
Target Oncol. 2016 Jun;11(3):417-28. doi: 10.1007/s11523-016-0443-8.
9
Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.BRAF 突变型黑色素瘤脑转移患者中 BRAF 抑制和 MEK 抑制的临床及影像学反应
Melanoma Res. 2018 Apr;28(2):126-133. doi: 10.1097/CMR.0000000000000429.
10
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.BRAF 和 MEK 联合抑制与单独 BRAF 抑制治疗黑色素瘤。
N Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.

引用本文的文献

1
Primary Undifferentiated/Dedifferentiated Cutaneous Melanomas-A Review on Histological, Immunohistochemical, and Molecular Features with Emphasis on Prognosis and Treatment.原发性未分化/去分化皮肤黑色素瘤——组织学、免疫组织化学和分子特征的综述，重点是预后和治疗。
Int J Mol Sci. 2023 Jun 10;24(12):9985. doi: 10.3390/ijms24129985.

本文引用的文献

1
Management of V600E and V600K BRAF-Mutant Melanoma.V600E 和 V600K BRAF 突变型黑色素瘤的治疗管理。
Curr Treat Options Oncol. 2019 Nov 18;20(11):81. doi: 10.1007/s11864-019-0680-z.
2
Uncommon Histopathological Variants of Malignant Melanoma. Part 2.恶性黑色素瘤的罕见组织病理学变异型。第2部分。
Am J Dermatopathol. 2019 May;41(5):321-342. doi: 10.1097/DAD.0000000000001226.
3
Uncommon Histopathological Variants of Malignant Melanoma: Part 1.恶性黑色素瘤的罕见组织病理学变异型：第1部分。
Am J Dermatopathol. 2019 Apr;41(4):243-263. doi: 10.1097/DAD.0000000000001218.
4
Osteogenic melanoma: report of a case mimicking osteosarcoma and review of the literature.成骨性黑色素瘤：1例酷似骨肉瘤病例报告并文献复习
Skeletal Radiol. 2018 May;47(5):711-716. doi: 10.1007/s00256-017-2835-y. Epub 2017 Dec 1.
5
Primary chondro-osseous melanoma (chondrosarcomatous and osteosarcomatous melanoma).原发性软骨骨黑素瘤（软骨肉瘤性和骨肉瘤性黑素瘤）。
J Cutan Pathol. 2018 Feb;45(2):146-150. doi: 10.1111/cup.13067. Epub 2017 Dec 6.
6
Chondrosarcomatous Differentiation in a Large Malignant Melanoma of the Scalp.头皮部巨大恶性黑色素瘤中的软骨肉瘤样分化
Case Rep Med. 2016;2016:1063569. doi: 10.1155/2016/1063569. Epub 2016 Dec 18.
7
Metastasectomy for Stage IV Melanoma in the Era of Effective Systemic Agents.有效全身治疗时代的IV期黑色素瘤转移灶切除术
Crit Rev Oncog. 2016;21(1-2):37-55. doi: 10.1615/CritRevOncog.2016014729.
8
Cartilaginous melanoma: case report and review of the literature.软骨性黑色素瘤：病例报告及文献综述
An Bras Dermatol. 2013 May-Jun;88(3):403-7. doi: 10.1590/abd1806-4841.20131595.
9
Chondroid melanoma metastatic to lung and skin showing SOX-9 expression: a potential diagnostic pitfall.转移至肺和皮肤的软骨样黑色素瘤显示SOX-9表达：一个潜在的诊断陷阱。
Int J Surg Pathol. 2012 Apr;20(2):169-72. doi: 10.1177/1066896911436275. Epub 2012 Feb 13.
10
Melanoma exhibiting cartilaginous differentiation.表现出软骨分化的黑色素瘤。
Histopathology. 2010 May;56(6):815-21. doi: 10.1111/j.1365-2559.2010.03536.x.